🌍·Jun 16, 2025Industry
AbelZeta Announces Promising Long-Term Outcomes for C-CAR039, a Novel CD19/CD20 Bi-Specific CAR-T Therapy, in Patients with R/R B NHL at EHA 2025
Publisher
A
AbelZeta Pharma
Global
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- AbelZeta Pharma
- Region
- Global
- Scope
- Industry
- Published
- June 16, 2025
In-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on abelzeta.com
Leave the platform to read the original full article on the publisher site.
Source: AbelZeta Pharma
Scope: Industry
Related coverage
More related coverage
Natco Pharma/9h ago
natco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26
Natco Pharma/9h ago
natco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26
Natco Pharma/9h ago
natco receives tentative approval for olaparib tablets from the united states food and drug administration u s fda
Natco Pharma/9h ago